{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:46:07Z","timestamp":1776872767117,"version":"3.51.2"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"DOI":"10.7759\/cureus.89942","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T04:20:41Z","timestamp":1755058841000},"source":"Crossref","is-referenced-by-count":1,"title":["A Bibliometric Analysis of Immunological Research in Primary Biliary Cholangitis: Global Patterns and Emerging Directions"],"prefix":"10.7759","author":[{"given":"Jinfeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wentao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danfeng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingren","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/srep25906","article-title":"Evolving trends in female to male incidence and male mortality of primary biliary cholangitis","volume":"6","author":"Lleo A","year":"2016","unstructured":"Lleo A, Jepsen P, Morenghi E, et al.. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis. Sci Rep. 2016, 6:25906. 10.1038\/srep25906","journal-title":"Sci Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2022.06.001","article-title":"Contemporary epidemiology of primary biliary cholangitis","volume":"26","author":"Colapietro F","year":"2022","unstructured":"Colapietro F, Bertazzoni A, Lleo A. Contemporary epidemiology of primary biliary cholangitis. Clin Liver Dis. 2022, 26:555-70. 10.1016\/j.cld.2022.06.001","journal-title":"Clin Liver Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield GM","year":"2018","unstructured":"Hirschfield GM, Dyson JK, Alexander GJ, et al.. The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018, 67:1568-94. 10.1136\/gutjnl-2017-315259","journal-title":"Gut"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score","volume":"3","author":"Carbone M","year":"2018","unstructured":"Carbone M, Nardi A, Flack S, et al.. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. Lancet Gastroenterol Hepatol. 2018, 3:626-34. 10.1016\/s2468-1253(18)30163-8","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2018.03.007","article-title":"Natural history of primary biliary cholangitis in the ursodeoxycholic acid era: role of scoring systems","volume":"22","author":"Goel A","year":"2018","unstructured":"Goel A, Kim WR. Natural history of primary biliary cholangitis in the ursodeoxycholic acid era: role of scoring systems. Clin Liver Dis. 2018, 22:563-78. 10.1016\/j.cld.2018.03.007","journal-title":"Clin Liver Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1565778","article-title":"Bibliometric analysis of research on intestinal flora and primary biliary cholangitis published between 2004 and 2024 using VOSviewer and CiteSpace visualization","volume":"12","author":"Li T","year":"2025","unstructured":"Li T, Jing W. Bibliometric analysis of research on intestinal flora and primary biliary cholangitis published between 2004 and 2024 using VOSviewer and CiteSpace visualization. Front Med (Lausanne). 2025, 12:1565778. 10.3389\/fmed.2025.1565778","journal-title":"Front Med (Lausanne)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00825-0","article-title":"The latest research trends in primary biliary cholangitis: a bibliometric analysis","volume":"23","author":"Zhao Y","year":"2023","unstructured":"Zhao Y, Yin Z, Du H, Huang K, Zhang F, Chen H. The latest research trends in primary biliary cholangitis: a bibliometric analysis. Clin Exp Med. 2023, 23:347-55. 10.1007\/s10238-022-00825-0","journal-title":"Clin Exp Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.03.031","article-title":"Bibliometric and visualized analysis of ocular drug delivery from 2001 to 2020","volume":"345","author":"Peng C","year":"2022","unstructured":"Peng C, Kuang L, Zhao J, Ross AE, Wang Z, Ciolino JB. Bibliometric and visualized analysis of ocular drug delivery from 2001 to 2020. J Control Release. 2022, 345:625-45. 10.1016\/j.jconrel.2022.03.031","journal-title":"J Control Release"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00564","article-title":"Trends in Sigma-1 receptor research: a 25-year bibliometric analysis","volume":"10","author":"Romero L","year":"2019","unstructured":"Romero L, Portillo-Salido E. Trends in Sigma-1 receptor research: a 25-year bibliometric analysis. Front Pharmacol. 2019, 10:564. 10.3389\/fphar.2019.00564","journal-title":"Front Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116504","article-title":"Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2","volume":"91","author":"Van de Water J","year":"1993","unstructured":"Van de Water J, Turchany J, Leung PS, et al.. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest. 1993, 91:2653-64. 10.1172\/JCI116504","journal-title":"J Clin Invest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199611213352107","article-title":"Primary biliary cirrhosis","volume":"335","author":"Kaplan MM","year":"1996","unstructured":"Kaplan MM. Primary biliary cirrhosis. N Engl J Med. 1996, 335:1570-80. 10.1056\/NEJM199611213352107","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0528.2002.017402.x","article-title":"Primary biliary cirrhosis: an orchestrated immune response against epithelial cells","volume":"174","author":"Gershwin ME","year":"2000","unstructured":"Gershwin ME, Ansari AA, Mackay IR, Nakanuma Y, Nishio A, Rowley MJ, Coppel RL. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev. 2000, 174:210-25. 10.1034\/j.1600-0528.2002.017402.x","journal-title":"Immunol Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20010956","article-title":"Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells","volume":"195","author":"Kita H","year":"2002","unstructured":"Kita H, Lian ZX, Van de Water J, et al.. Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med. 2002, 195:113-23. 10.1084\/jem.20010956","journal-title":"J Exp Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.05.005","article-title":"Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment","volume":"127","author":"Selmi C","year":"2004","unstructured":"Selmi C, Mayo MJ, Bach N, et al.. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology. 2004, 127:485-92. 10.1053\/j.gastro.2004.05.005","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan MM","year":"2005","unstructured":"Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005, 353:1261-73. 10.1056\/NEJMra043898","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20907","article-title":"Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients","volume":"42","author":"Gershwin ME","year":"2005","unstructured":"Gershwin ME, Selmi C, Worman HJ, et al.. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005, 42:1194-202. 10.1002\/hep.20907","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.3.1655","article-title":"Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice","volume":"177","author":"Oertelt S","year":"2006","unstructured":"Oertelt S, Lian ZX, Cheng CM, et al.. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol. 2006, 177:1655-60. 10.4049\/jimmunol.177.3.1655","journal-title":"J Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22042","article-title":"The causes of primary biliary cirrhosis: convenient and inconvenient truths","volume":"47","author":"Gershwin ME","year":"2008","unstructured":"Gershwin ME, Mackay IR. The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology. 2008, 47:737-45. 10.1002\/hep.22042","journal-title":"Hepatology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810440","article-title":"Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants","volume":"360","author":"Hirschfield GM","year":"2009","unstructured":"Hirschfield GM, Liu X, Xu C, et al.. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009, 360:2544-55. 10.1056\/NEJMoa0810440","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor KD","year":"2009","unstructured":"Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology. 2009, 50:291-308. 10.1002\/hep.22906","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/ng.627","article-title":"Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis","volume":"42","author":"Liu X","year":"2010","unstructured":"Liu X, Invernizzi P, Lu Y, et al.. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet. 2010, 42:658-60. 10.1038\/ng.627","journal-title":"Nat Genet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/ng.789","article-title":"Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis","volume":"43","author":"Mells GF","year":"2011","unstructured":"Mells GF, Floyd JA, Morley KI, et al.. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2011, 43:329-32. 10.1038\/ng.789","journal-title":"Nat Genet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020712-164014","article-title":"The immunobiology and pathophysiology of primary biliary cirrhosis","volume":"8","author":"Hirschfield GM","year":"2013","unstructured":"Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol. 2013, 8:303-30. 10.1146\/annurev-pathol-020712-164014","journal-title":"Annu Rev Pathol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26979","article-title":"IL-12\/Th1 and IL-23\/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy","volume":"59","author":"Yang CY","year":"2014","unstructured":"Yang CY, Ma X, Tsuneyama K, et al.. IL-12\/Th1 and IL-23\/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology. 2014, 59:1944-53. 10.1002\/hep.26979","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey EJ","year":"2015","unstructured":"Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015, 386:1565-75. 10.1016\/s0140-6736(15)00154-3","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens F","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, et al.. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016, 375:631-43. 10.1056\/NEJMoa1509840","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","unstructured":"EASL Clinical Practice Guidelines. The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017, 67:145-72. 10.1016\/j.jhep.2017.03.022","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30145","article-title":"Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor KD","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019, 69:394-419. 10.1002\/hep.30145","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot C","year":"2018","unstructured":"Corpechot C, Chazouill\u00e8res O, Rousseau A, et al.. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018, 378:2171-81. 10.1056\/NEJMoa1714519","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28965","article-title":"The ascending pathophysiology of cholestatic liver disease","volume":"65","author":"Jansen PL","year":"2017","unstructured":"Jansen PL, Ghallab A, Vartak N, Reif R, Schaap FG, Hampe J, Hengstler JG. The ascending pathophysiology of cholestatic liver disease. Hepatology. 2017, 65:722-38. 10.1002\/hep.28965","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(88)91894-6","article-title":"Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens","volume":"1","author":"Yeaman SJ","year":"1988","unstructured":"Yeaman SJ, Danner DJ, Mutimer DJ, et al.. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet. 1988, 1:1067-70. 10.1016\/s0140-6736(88)91894-6","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers WJ","year":"2015","unstructured":"Lammers WJ, Hirschfield GM, Corpechot C, et al.. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015, 149:1804-12. 10.1053\/j.gastro.2015.07.061","journal-title":"Gastroenterology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura M","year":"2007","unstructured":"Nakamura M, Kondo H, Mori T, et al.. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007, 45:118-27. 10.1002\/hep.21472","journal-title":"Hepatology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21385","article-title":"IL-2 receptor alpha(-\/-) mice and the development of primary biliary cirrhosis","volume":"44","author":"Wakabayashi K","year":"2006","unstructured":"Wakabayashi K, Lian ZX, Moritoki Y, et al.. IL-2 receptor alpha(-\/-) mice and the development of primary biliary cirrhosis. Hepatology. 2006, 44:1240-9. 10.1002\/hep.21385","journal-title":"Hepatology"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.138.10.3525","article-title":"Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis","volume":"138","author":"Gershwin ME","year":"1987","unstructured":"Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol. 1987, 138:3525-31. 10.4049\/jimmunol.138.10.3525","journal-title":"J Immunol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.03.008","article-title":"Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease","volume":"41","author":"Longhi MS","year":"2004","unstructured":"Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004, 41:31-7. 10.1016\/j.jhep.2004.03.008","journal-title":"J Hepatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.03898.x","article-title":"Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population","volume":"156","author":"Rong G","year":"2009","unstructured":"Rong G, Zhou Y, Xiong Y, et al.. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin Exp Immunol. 2009, 156:217-25. 10.1111\/j.1365-2249.2009.03898.x","journal-title":"Clin Exp Immunol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-022-00940-w","article-title":"Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease","volume":"44","author":"Richardson N","year":"2022","unstructured":"Richardson N, Wootton GE, Bozward AG, Oo YH. Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease. Semin Immunopathol. 2022, 44:461-74. 10.1007\/s00281-022-00940-w","journal-title":"Semin Immunopathol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103327","article-title":"Identification of a novel PDC-E2 epitope in primary biliary cholangitis: application for engineered Treg therapy","volume":"149","author":"Tewari R","year":"2024","unstructured":"Tewari R, Yang SJ, McClain ED, et al.. Identification of a novel PDC-E2 epitope in primary biliary cholangitis: application for engineered Treg therapy. J Autoimmun. 2024, 149:103327. 10.1016\/j.jaut.2024.103327","journal-title":"J Autoimmun"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI130670","article-title":"Ubiquitous antigen-specific T regulatory type 1 cells variably suppress hepatic and extrahepatic autoimmunity","volume":"130","author":"Umeshappa CS","year":"2020","unstructured":"Umeshappa CS, Mbongue J, Singha S, et al.. Ubiquitous antigen-specific T regulatory type 1 cells variably suppress hepatic and extrahepatic autoimmunity. J Clin Invest. 2020, 130:1823-9. 10.1172\/JCI130670","journal-title":"J Clin Invest"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy","volume":"67","author":"Tang R","year":"2018","unstructured":"Tang R, Wei Y, Li Y, et al.. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut. 2018, 67:534-41. 10.1136\/gutjnl-2016-313332","journal-title":"Gut"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.07.002","article-title":"Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases","volume":"16","author":"Li Y","year":"2017","unstructured":"Li Y, Tang R, Leung PS, Gershwin ME, Ma X. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev. 2017, 16:885-96. 10.1016\/j.autrev.2017.07.002","journal-title":"Autoimmun Rev"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-022-00935-7","article-title":"Bile acids and their receptors: modulators and therapeutic targets in liver inflammation","volume":"44","author":"Bertolini A","year":"2022","unstructured":"Bertolini A, Fiorotto R, Strazzabosco M. Bile acids and their receptors: modulators and therapeutic targets in liver inflammation. Semin Immunopathol. 2022, 44:547-64. 10.1007\/s00281-022-00935-7","journal-title":"Semin Immunopathol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley KV","year":"2018","unstructured":"Kowdley KV, Luketic V, Chapman R, et al.. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology. 2018, 67:1890-902. 10.1002\/hep.29569","journal-title":"Hepatology"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2305-5839.2014.12.06","article-title":"Recent advances in the development of farnesoid X receptor agonists","volume":"3","author":"Ali AH","year":"2015","unstructured":"Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015, 3:5. 10.3978\/j.issn.2305-5839.2014.12.06","journal-title":"Ann Transl Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(19)30343-7","article-title":"Current and potential treatments for primary biliary cholangitis","volume":"5","author":"Shah RA","year":"2020","unstructured":"Shah RA, Kowdley KV. Current and potential treatments for primary biliary cholangitis. Lancet Gastroenterol Hepatol. 2020, 5:306-15. 10.1016\/s2468-1253(19)30343-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32405","article-title":"Mechanisms and molecules: what are the treatment targets for primary biliary cholangitis?","volume":"76","author":"Mayo MJ","year":"2022","unstructured":"Mayo MJ. Mechanisms and molecules: what are the treatment targets for primary biliary cholangitis?. Hepatology. 2022, 76:518-31. 10.1002\/hep.32405","journal-title":"Hepatology"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.08.006","article-title":"Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis","volume":"75","author":"Hisamoto S","year":"2016","unstructured":"Hisamoto S, Shimoda S, Harada K, et al.. Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis. J Autoimmun. 2016, 75:150-60. 10.1016\/j.jaut.2016.08.006","journal-title":"J Autoimmun"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000110","article-title":"Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells","volume":"7","author":"Mulcahy V","year":"2023","unstructured":"Mulcahy V, Liaskou E, Martin JE, et al.. Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells. Hepatol Commun. 2023, 7:14-6. 10.1097\/HC9.0000000000000110","journal-title":"Hepatol Commun"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-023-01170-9","article-title":"Animal models of primary biliary cholangitis: status and challenges","volume":"13","author":"Wang X","year":"2023","unstructured":"Wang X, Wei Y, Yang Y, et al.. Animal models of primary biliary cholangitis: status and challenges. Cell Biosci. 2023, 13:214. 10.1186\/s13578-023-01170-9","journal-title":"Cell Biosci"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34606-w","article-title":"Unique DUOX2(+)ACE2(+) small cholangiocytes are pathogenic targets for primary biliary cholangitis","volume":"14","author":"Li X","year":"2023","unstructured":"Li X, Li Y, Xiao J, et al.. Unique DUOX2(+)ACE2(+) small cholangiocytes are pathogenic targets for primary biliary cholangitis. Nat Commun. 2023, 14:29. 10.1038\/s41467-022-34606-w","journal-title":"Nat Commun"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone M","year":"2016","unstructured":"Carbone M, Sharp SJ, Flack S, et al.. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology. 2016, 63:930-50. 10.1002\/hep.28017","journal-title":"Hepatology"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10586-x","article-title":"ChIP-seq analysis found IL21R, a target gene of GTF2I-the susceptibility gene for primary biliary cholangitis in Chinese Han","volume":"18","author":"Wu Z","year":"2024","unstructured":"Wu Z, Li H, Xu H, et al.. ChIP-seq analysis found IL21R, a target gene of GTF2I-the susceptibility gene for primary biliary cholangitis in Chinese Han. Hepatol Int. 2024, 18:509-16. 10.1007\/s12072-023-10586-x","journal-title":"Hepatol Int"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000894","article-title":"A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis","volume":"80","author":"Hitomi Y","year":"2024","unstructured":"Hitomi Y, Ueno K, Aiba Y, et al.. A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis. Hepatology. 2024, 80:776-90. 10.1097\/HEP.0000000000000894","journal-title":"Hepatology"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15916","article-title":"Improving predictive accuracy in primary biliary cholangitis: a\u00a0new genetic risk score","volume":"44","author":"Gerussi A","year":"2024","unstructured":"Gerussi A, Cappadona C, Bernasconi DP, et al.. Improving predictive accuracy in primary biliary cholangitis: a\u00a0new genetic risk score. Liver Int. 2024, 44:1952-60. 10.1111\/liv.15916","journal-title":"Liver Int"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02114-4","article-title":"Seladelpar: first approval","volume":"84","author":"Hoy SM","year":"2024","unstructured":"Hoy SM. Seladelpar: first approval. Drugs. 2024, 84:1487-95. 10.1007\/s40265-024-02114-4","journal-title":"Drugs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/398076-a-bibliometric-analysis-of-immunological-research-in-primary-biliary-cholangitis-global-patterns-and-emerging-directions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T04:20:44Z","timestamp":1755058844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/398076-a-bibliometric-analysis-of-immunological-research-in-primary-biliary-cholangitis-global-patterns-and-emerging-directions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":56,"URL":"https:\/\/doi.org\/10.7759\/cureus.89942","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}